{"filing":{"accession_number":"0001193125-26-318056","cik":"0001671584","ticker":"APVO","company_name":"Aptevo Therapeutics Inc.","form":"8-K","filing_date":"2026-07-27","report_date":"2026-07-27","primary_document":"apvo-20260727.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526318056/apvo-20260727.htm"},"events":[{"id":20660,"run_id":18598,"accession_number":"0001193125-26-318056","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Aptevo announced a new solid tumor strategy and filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen its oncology pipeline and expand partnering opportunities. This is a strategic operational and scientific milestone—a platform innovation that supports multiple therapeutic approaches—rather than a specific financial, governance, or legal event. The filing strengthens IP protection and represents a material strategic pivot in the company's pipeline development approach, making it material to investors assessing the company's oncology strategy and future value creation.","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20087,"accession_number":"0001193125-26-318056","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo announced a new solid tumor strategy and filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen its oncology pipeline and expand partnering opportunities. This is a strategic operational and scientific milestone—a platform innovation that supports multiple therapeutic approaches—rather than a specific financial, governance, or legal event. The filing strengthens IP protection and represents a material strategic pivot in the company's pipeline development approach, making it material to investors assessing the company's oncology strategy and future value creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:09:31.275621+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20087,"accession_number":"0001193125-26-318056","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo announced a new solid tumor strategy and filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen its oncology pipeline and expand partnering opportunities. This is a strategic operational and scientific milestone—a platform innovation that supports multiple therapeutic approaches—rather than a specific financial, governance, or legal event. The filing strengthens IP protection and represents a material strategic pivot in the company's pipeline development approach, making it material to investors assessing the company's oncology strategy and future value creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:09:31.275621+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-07-27"}]}